Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 21 Analysts
Published
10 Aug 25
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$62.43
21.5% undervalued intrinsic discount14 Aug
US$49.02
1Y
94.8%7D
1.6%